No Data
No Data
The Recent CN¥800m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773)
Key Insights Chengdu Kanghong Pharmaceutical Group's significant insider ownership suggests inherent interests in company's expansion 54% of the business is held by the top 2 shareholders Using da
Kanghong Pharmaceutical (002773.SZ) plans to pay 3.8 yuan for every 10 shares in 2023, excluding interest on May 28
Kanghong Pharmaceutical (002773.SZ) announced that in 2023, the company plans to distribute cash red to all shareholders for every 10 shares...
Kanghong Pharmaceutical (002773.SZ): As of May 20, 2024, the number of shareholders of the company was 35,384
Gelonghui, May 21丨Kanghong Pharmaceutical (002773.SZ) said on the investor interactive platform that as of May 20, 2024, the number of shareholders of the company was 35,384.
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Held Back By Insufficient Growth Even After Shares Climb 25%
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) shares have continued their recent momentum with a 25% gain in the last month alone. Taking a wider view, although not as strong as the
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug
Chengdu Kanghong Pharmaceutical Group's (SHE:002773) unit, Chengdu Hongji Biotechnology, will conduct clinical trials on the KH658 ophthalmic injection after receiving approval from China's National M
Kanghong Pharmaceutical (002773.SZ): Clinical trial of KH658 ophthalmic injection approved
According to Zhitong Finance App, Kanghong Pharmaceutical (002773.SZ) issued an announcement. On April 28, 2024, the KH658 ophthalmic injection declared by the company's subsidiary Chengdu Hongji Biotechnology Co., Ltd. obtained an approval notice for drug clinical trials from the China Drug Administration and agreed to carry out phase I/II clinical trials. According to reports, KH658 ophthalmic injection is the second product of Hongji Biotech to be approved for clinical trials in China and the US at the same time. It uses a novel adeno-associated virus with independent intellectual property rights and a cell-specific receptor design as a delivery carrier. It is easy to administer, is safe, and has cell-mediated efficacy
No Data